A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors
Colorectal Cancer Metastatic|Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Bladder Cancer|GastroEsophageal Cancer|Renal Cell Carcinoma|MSI-H
BIOLOGICAL: EDP1503|BIOLOGICAL: Pembrolizumab
Safety and tolerability of EDP1503 alone and in combination with pembrolizumab as assessed per CTCAE v5.0, Number of participants with EPD1503 related adverse events as assessed per CTCAE v5.0, 2 years|Safety and tolerability of EDP1503 alone and in combination with pembrolizumab, Safety and tolerability of EDP1503 alone and in combination with pembrolizumab assessed via clinical laboratory evaluations, 2 years|Evidence of anti-tumor activity of EDP1503 based on ORR, To determine preliminary evidence of anti-tumor activity of EDP1503 in patients, 2 years
Progression Free Survival, Progression Free Survival, 2 years|Overall Survival, Overall Survival, 2 years
This will be a Phase I open-label study which will involve a 2-week monotherapy with EDP1503, following which the patients will be dosed with a combination of EDP1503 and pembrolizumab.